Seattle Genetics Total Liabilities 2006-2019 | SGEN

Seattle Genetics total liabilities from 2006 to 2019. Total liabilities can be defined as the total value of all possible claims against the corporation.
  • Seattle Genetics total liabilities for the quarter ending June 30, 2019 were $0.296B, a 49% increase year-over-year.
  • Seattle Genetics total liabilities for 2018 were $0.229B, a 14.48% increase from 2017.
  • Seattle Genetics total liabilities for 2017 were $0.2B, a 1.92% decline from 2016.
  • Seattle Genetics total liabilities for 2016 were $0.204B, a 2.33% decline from 2015.
Seattle Genetics Annual Total Liabilities
(Millions of US $)
2018 $229
2017 $200
2016 $204
2015 $209
2014 $248
2013 $254
2012 $245
2011 $206
2010 $168
2009 $182
2008 $109
2007 $95
2006 $9
2005 $15
Seattle Genetics Quarterly Total Liabilities
(Millions of US $)
Q2 2019 $296
Q1 2019 $279
Q4 2018 $229
Q3 2018 $203
Q2 2018 $198
Q1 2018 $194
Q4 2017 $200
Q3 2017 $193
Q2 2017 $184
Q1 2017 $181
Q4 2016 $204
Q3 2016 $188
Q2 2016 $195
Q1 2016 $195
Q4 2015 $209
Q3 2015 $211
Q2 2015 $228
Q1 2015 $237
Q4 2014 $248
Q3 2014 $253
Q2 2014 $244
Q1 2014 $245
Q4 2013 $254
Q3 2013 $243
Q2 2013 $229
Q1 2013 $233
Q4 2012 $245
Q3 2012 $193
Q2 2012 $202
Q1 2012 $192
Q4 2011 $206
Q3 2011 $189
Q2 2011 $190
Q1 2011 $176
Q4 2010 $168
Q3 2010 $159
Q2 2010 $140
Q1 2010 $146
Q4 2009 $182
Q3 2009 $111
Q2 2009 $113
Q1 2009 $113
Q4 2008 $109
Q3 2008 $108
Q2 2008 $102
Q1 2008 $99
Q4 2007 $95
Q3 2007 $77
Q2 2007 $74
Q1 2007 $73
Q4 2006 $9
Q3 2006 $11
Q2 2006 $12
Q1 2006 $13
Q4 2005 $15
Q3 2005 $16
Q2 2005 $18
Q1 2005 $15
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $13.898B $0.655B
Seattle Genetics is a biotechnology company focused on the development and commercialization of innovative antibody-based therapies for the treatment of cancer. Seattle Genetics is leading the field in developing antibody-drug conjugates (ADCs), a technology designed to harness the targeting ability of antibodies to deliver cell-killing agents directly to cancer cells. The company's lead product, ADCETRIS? (brentuximab vedotin) is an ADC that, in collaboration with Takeda Pharmaceutical Company Limited, is commercially available for two indications in more than 45 countries, including the U.S., Canada, Japan and members of the European Union. Additionally, ADCETRIS is being evaluated broadly in more than 30 ongoing clinical trials. Seattle Genetics is also advancing a robust pipeline of clinical-stage ADC programs, including SGN-CD19A, SGN-CD33A, SGN-LIV1A, SGN-CD70A, ASG-22ME and ASG-15ME.
Stock Name Country Market Cap PE Ratio
Amgen (AMGN) United States $122.075B 13.90
Gilead Sciences (GILD) United States $82.611B 10.15
CSL (CSLLY) Australia $77.981B 0.00
Celgene (CELG) United States $72.150B 11.16
Vertex Pharmaceuticals (VRTX) United States $45.680B 49.37
Illumina (ILMN) United States $45.651B 53.64
Biogen (BIIB) United States $41.611B 7.39
Regeneron Pharmaceuticals (REGN) United States $33.122B 15.03
Alexion Pharmaceuticals (ALXN) United States $22.420B 11.82
SINO PHARMACEUT (SBMFF) Hong Kong, SAR China $18.379B 0.00
Incyte (INCY) United States $16.653B 49.01
Genmab (GNMSF) Denmark $12.636B 70.88
Exact Sciences (EXAS) United States $12.611B 0.00
BioMarin Pharmaceutical (BMRN) United States $12.186B 0.00
Bio-Rad Laboratories (BIO.B) United States $10.175B 54.54
Alnylam Pharmaceuticals (ALNY) United States $9.106B 0.00
Galapagos (GLPG) Belgium $8.936B 0.00
Bio-Techne Corp (TECH) United States $7.635B 52.75
Sarepta Therapeutics (SRPT) United States $6.500B 0.00
QIAGEN (QGEN) Netherlands $6.355B 20.87
BeiGene (BGNE) Cayman Islands $6.328B 0.00
Guardant Health (GH) United States $6.299B 0.00
Amarin (AMRN) Ireland $5.855B 0.00
ACADIA Pharmaceuticals (ACAD) United States $5.777B 0.00
Horizon Therapeutics Public (HZNP) Ireland $5.310B 13.50
Reata Pharmaceuticals (RETA) United States $5.214B 0.00
Exelixis (EXEL) United States $5.149B 13.39
Bluebird Bio (BLUE) United States $5.048B 0.00
Moderna (MRNA) United States $4.801B 0.00
China Biologic Products (CBPO) China $4.553B 28.42
ARGENX SE-ADR (ARGX) Netherlands $4.494B 0.00
Medicines (MDCO) United States $4.443B 0.00
Ascendis Pharma (ASND) Denmark $4.217B 0.00
Repligen (RGEN) United States $4.084B 79.26
Spark Therapeutics (ONCE) United States $3.887B 0.00
Blueprint Medicines (BPMC) United States $3.673B 0.00
MorphoSys AG (MOR) Germany $3.482B 0.00
Mirati Therapeutics (MRTX) United States $3.422B 0.00
Immunomedics (IMMU) United States $3.045B 0.00
Emergent Biosolutions (EBS) United States $2.795B 41.99
Alkermes (ALKS) Ireland $2.786B 0.00
Genmab (GMAB) Denmark $2.701B 0.00
Genomic Health (GHDX) United States $2.632B 49.36
MyoKardia (MYOK) United States $2.625B 0.00
Ultragenyx Pharmaceutical (RARE) United States $2.532B 0.00
Arena Pharmaceuticals (ARNA) United States $2.437B 5.24
Halozyme Therapeutics (HALO) United States $2.312B 0.00
Acceleron Pharma (XLRN) United States $2.279B 0.00
Myriad Genetics (MYGN) United States $2.263B 23.58
RA PHARMCTL INC (RARX) United States $2.198B 0.00
NeoGenomics (NEO) United States $2.122B 113.50
Intercept Pharmaceuticals (ICPT) United States $2.106B 0.00
Amicus Therapeutics (FOLD) United States $2.083B 0.00
CRISPR Therapeutics AG (CRSP) Switzerland $2.072B 0.00
Ligand Pharmaceuticals (LGND) United States $2.057B 26.00
Cambrex (CBM) United States $2.002B 25.32
Zai Lab (ZLAB) China $1.983B 0.00
Akcea Therapeutics (AKCA) United States $1.761B 0.00
UniQure (QURE) Netherlands $1.674B 0.00
Alder BioPharmaceuticals (ALDR) United States $1.585B 0.00
Insmed (INSM) United States $1.564B 0.00
Nabriva Therapeutics AG (NBRV) Ireland $1.504B 0.00
Denali Therapeutics (DNLI) United States $1.451B 0.00
REGENXBIO (RGNX) United States $1.437B 0.00
Momenta Pharmaceuticals (MNTA) United States $1.397B 0.00
Coherus BioSciences (CHRS) United States $1.339B 0.00
Orchard Therapeutics (ORTX) United Kingdom $1.210B 0.00
Zymeworks (ZYME) Canada $1.176B 0.00
Innoviva (INVA) United States $1.107B 3.20
Dicerna Pharmaceuticals (DRNA) United States $1.080B 0.00
Alector (ALEC) United States $1.036B 0.00
AnaptysBio (ANAB) United States $1.009B 0.00
Editas Medicine (EDIT) United States $1.008B 0.00
Sangamo Therapeutics (SGMO) United States $0.998B 0.00
Fate Therapeutics (FATE) United States $0.960B 0.00
Epizyme (EPZM) United States $0.953B 0.00
ANI Pharmaceuticals (ANIP) United States $0.888B 14.83
Achillion Pharmaceuticals (ACHN) United States $0.866B 0.00
Zealand Pharma (ZEAL) Denmark $0.865B 9.71
BAVARIAN NORDIC (BVNRY) Denmark $0.856B 0.00
Athenex (ATNX) United States $0.835B 0.00
Codexis (CDXS) United States $0.808B 0.00
Twist Bioscience (TWST) United States $0.806B 0.00
Anika Therapeutics (ANIK) United States $0.803B 28.43
Cara Therapeutics (CARA) United States $0.788B 0.00
Principia Biopharma (PRNB) United States $0.761B 394.00
Vanda Pharmaceuticals (VNDA) United States $0.729B 26.31
Pharming Group (PHGUF) Netherlands $0.724B 0.00
Zealand Pharma (ZLDPF) Denmark $0.722B 0.00
WAVE Life Sciences (WVE) Singapore $0.721B 0.00
Vericel (VCEL) United States $0.684B 0.00
Revance Therapeutics (RVNC) United States $0.676B 0.00
Cytokineticsorporated (CYTK) United States $0.665B 0.00
ZIOPHARM Oncology Inc (ZIOP) United States $0.644B 0.00
Mesoblast (MESO) Australia $0.619B 0.00
Heska (HSKA) United States $0.596B 77.27
GENFIT S.A (GNFT) France $0.560B 0.00
MiMedx (MDXG) United States $0.556B 0.00
Intellia Therapeutics (NTLA) United States $0.555B 0.00
Arvinas (ARVN) United States $0.524B 0.00
Autolus Therapeutics (AUTL) United Kingdom $0.519B 0.00
Basilea Pharmaceutica AG (BPMUF) Switzerland $0.502B 0.00
PHARMA MAR SA (PHMMF) Spain $0.494B 0.00
Retrophin (RTRX) United States $0.491B 0.00
DBV Technologies S.A (DBVT) France $0.474B 0.00
Intra-Cellular Therapies (ITCI) United States $0.469B 0.00
UROGEN PHARMA (URGN) United States $0.468B 0.00
OXFORD BIOMEDCL (OXBDF) United Kingdom $0.462B 0.00
BioDelivery Sciences (BDSI) United States $0.461B 0.00
Sinovac Biotech (SVA) China $0.460B 0.00
Adverum Biotechnologies (ADVM) United States $0.454B 0.00
Cellectis S.A (CLLS) France $0.448B 0.00
Stemline Therapeutics (STML) United States $0.396B 0.00
Bellus Health (BLU) Canada $0.393B 0.00
AMAG Pharmaceuticals (AMAG) United States $0.387B 0.00
Arcus Biosciences (RCUS) United States $0.386B 0.00
Merus (MRUS) Netherlands $0.376B 0.00
Agenus (AGEN) United States $0.368B 0.00
Kadmon Holdings (KDMN) United States $0.364B 0.00
Lexicon Pharmaceuticals (LXRX) United States $0.346B 0.00
Precision BioSciences (DTIL) United States $0.345B 0.00
AC Immune SA (ACIU) Switzerland $0.334B 24.75
CytomX Therapeutics (CTMX) United States $0.323B 0.00
Prothena (PRTA) Ireland $0.320B 0.00
Protagonist Therapeutics (PTGX) United States $0.317B 0.00
Avid Bioservices (CDMO) United States $0.299B 0.00
Gritstone Oncology (GRTS) United States $0.298B 0.00
Syros Pharmaceuticals (SYRS) United States $0.295B 0.00
Kindred Biosciences (KIN) United States $0.292B 0.00
Cel-Sci (CVM) United States $0.289B 0.00
Cellular Biomedicine (CBMG) United States $0.287B 0.00
Pfenex (PFNX) United States $0.281B 0.00
Geron (GERN) United States $0.281B 0.00
Scholar Rock Holding (SRRK) United States $0.280B 0.00
Starpharma Holdings (SPHRY) Australia $0.279B 0.00
PDL BioPharma (PDLI) United States $0.278B 7.15
Dynavax Technologies (DVAX) United States $0.276B 0.00
EYEPOINT PHARMACEUTICALS, INC (EYPT) United States $0.271B 0.00
Biofrontera AG (BFRA) Germany $0.265B 395.33
Theratechnologies (THTX) Canada $0.263B 0.00
ADMA Biologics Inc (ADMA) United States $0.262B 0.00
Puma Biotechnology (PBYI) United States $0.260B 0.00
Seres Therapeutics (MCRB) United States $0.243B 0.00
MannKind (MNKD) United States $0.243B 0.00
Inovio Pharmaceuticals (INO) United States $0.234B 0.00
OSMOTICA PHARM (OSMT) United States $0.232B 0.00
Sutro Biopharma (STRO) United States $0.230B 0.00
Xenon Pharmaceuticals (XENE) Canada $0.230B 0.00
Aeglea BioTherapeutics (AGLE) United States $0.228B 0.00
Albireo Pharma (ALBO) United States $0.227B 0.00
Sorrento Therapeutics (SRNE) United States $0.219B 0.00
Kamada (KMDA) Israel $0.213B 8.14
Spero Therapeutics (SPRO) United States $0.212B 0.00
Athersys (ATHX) United States $0.211B 0.00
Exicure (XCUR) United States $0.205B 0.00
Compugen (CGEN) Israel $0.205B 0.00
POXEL SA FRANCE (PXXLF) France $0.204B 0.00
Clovis Oncology (CLVS) United States $0.200B 0.00
ChromaDex (CDXC) United States $0.198B 0.00
Affimed (AFMD) Germany $0.191B 0.00
Palatin Technologies (PTN) United States $0.190B 5.57
Syndax Pharmaceuticals (SNDX) United States $0.189B 0.00
Prometic Life Sciences (PFSCF) Canada $0.177B 0.00
Dyadic (DYAI) United States $0.177B 0.00
Nicox SA (NICXF) France $0.175B 0.00
Bicycle Therapeutics (BCYC) United Kingdom $0.170B 0.00
Newron Pharmaceuticals SpA (NWPHF) $0.165B 0.00
Senesco Technologies (ELOX) United States $0.164B 0.00
Cue Biopharma (CUE) United States $0.163B 0.00
Pieris Pharmaceuticals (PIRS) United States $0.162B 0.00
XOMA (XOMA) United States $0.161B 0.00
Enzo Biochem (ENZ) United States $0.154B 0.00
Cerecor (CERC) United States $0.153B 0.00
Arsanis (XFOR) United States $0.153B 0.00
Five Prime Therapeutics (FPRX) United States $0.150B 0.00
CorMedix Inc (CRMD) United States $0.148B 0.00
AVEO Pharmaceuticals (AVEO) United States $0.148B 0.00
Alcobra (ARCT) United States $0.146B 0.00
BioTime (LCTX) United States $0.144B 9.60
Northwest Biotherapeutics (NWBO) United States $0.134B 0.00
Acorda Therapeutics (ACOR) United States $0.124B 0.00
SESEN BIO, INC (SESN) United States $0.121B 0.00
NantKwest (NK) United States $0.119B 0.00
Emmaus Life Sciences (EMMA) United States $0.118B 0.00
Nymox Pharmaceutical (NYMX) Canada $0.117B 0.00
PHASEBIO PHARMA (PHAS) United States $0.116B 0.00
Paratek Pharmaceuticals (PRTK) United States $0.113B 0.00
Abeona Therapeutics (ABEO) United States $0.111B 0.00
Novavax (NVAX) United States $0.111B 0.00
Menlo Therapeutics (MNLO) United States $0.110B 0.00
Aptinyx (APTX) United States $0.109B 0.00
Strongbridge Biopharma (SBBP) United States $0.109B 4.47
Adaptimmune Therapeutics (ADAP) United Kingdom $0.105B 0.00
Windtree Therapeutics (WINT) United States $0.103B 0.00
OvaScience (MLND) United States $0.097B 0.00
Celyad SA (CYAD) Belgium $0.097B 0.00
VBI Vaccines (VBIV) United States $0.096B 0.00
Fortress Biotech (FBIO) United States $0.090B 0.00
Trevena (TRVN) United States $0.089B 0.00
Liquidia Technologies (LQDA) United States $0.089B 0.00
Antibe Therapeutics (ATBPF) Canada $0.087B 0.00
Aduro Biotech (ADRO) United States $0.087B 0.00
Adocia (ADOCY) France $0.086B 0.00
Verastem (VSTM) United States $0.084B 0.00
Vaccinex (VCNX) United States $0.083B 0.00
Mersana Therapeutics (MRSN) United States $0.079B 0.00
Idera Pharmaceuticals (IDRA) United States $0.078B 0.00
Checkpoint Therapeutics (CKPT) United States $0.078B 0.00
VTv Therapeutics (VTVT) United States $0.077B 0.00
Aquinox Pharmaceuticals (NLTX) Canada $0.077B 0.00
ANIXA BIOSCIENCES INC (ANIX) United States $0.074B 0.00
ARAVIVE, INC (ARAV) United States $0.073B 0.00
Prima BioMed (IMMP) Australia $0.072B 0.00
Curis (CRIS) United States $0.071B 0.00
Synlogic (SYBX) United States $0.070B 0.00
Catalyst Biosciences (CBIO) United States $0.067B 0.00
Sunesis Pharmaceuticals (SNSS) United States $0.065B 0.00
Selecta Biosciences (SELB) United States $0.063B 0.00
Orgenesis (ORGS) United States $0.060B 21.82
AquaBounty Technologies (AQB) United States $0.057B 0.00
Pluristem Therapeutics (PSTI) Israel $0.057B 0.00
Applied Genetic Technologies (AGTC) United States $0.057B 0.00
Catabasis Pharmaceuticals (CATB) United States $0.056B 0.00
Merrimack Pharmaceuticals (MACK) United States $0.056B 0.00
Aridis Pharmaceuticals (ARDS) United States $0.054B 0.00
Arbutus Biopharma (ABUS) Canada $0.053B 0.00
ASLAN Pharmaceuticals (ASLN) Singapore $0.051B 0.00
Unum Therapeutics (UMRX) United States $0.051B 0.00
VistaGen Therapeutics (VTGN) United States $0.050B 0.00
AIT Therapeutics (XAIR) United States $0.048B 0.00
NewLink Genetics (NLNK) United States $0.047B 0.00
Protalix BioTherapeutics (PLX) Israel $0.047B 0.00
Vascular Biogenics (VBLT) Israel $0.047B 0.00
Spring Bank Pharmaceuticals (SBPH) United States $0.047B 0.00
VIVUS (VVUS) United States $0.044B 0.00
Evogene (EVGN) Israel $0.042B 0.00
AmpliPhi Biosciences (ARMP) United States $0.042B 0.00
Ophthotech (ISEE) United States $0.041B 0.00
Stellar Biotechnologies (EDSA) Canada $0.038B 0.00
INNOVATE BIOPHARMACEUTICALS, INC (INNT) United States $0.037B 0.00
Proteostasis Therapeutics (PTI) United States $0.037B 0.00
Organovo Holdings (ONVO) United States $0.037B 0.00
Oncobiologics (OTLK) United States $0.037B 0.00
Celsion (CLSN) United States $0.036B 0.00
Celldex Therapeutics (CLDX) United States $0.036B 0.00
DiaMedica Therapeutics (DMAC) United States $0.031B 0.00
Clearside Biomedical (CLSD) United States $0.031B 0.00
Aptevo Therapeutics (APVO) United States $0.029B 0.00
Signal Genetics (MGEN) United States $0.029B 0.00
Fibrocell Science Inc (FCSC) United States $0.029B 9.87
BioCardia (BCDA) United States $0.029B 0.00
Entera Bio (ENTX) Israel $0.027B 0.00
Alimera Sciences (ALIM) United States $0.026B 0.00
Caladrius Biosciences (CLBS) United States $0.024B 0.00
Aytu Bioscience (AYTU) United States $0.022B 0.00
Apricus Biosciences (SEEL) United States $0.021B 0.00
Novogen (KZIA) Australia $0.021B 0.00
Aerpio Pharmaceuticals (ARPO) United States $0.020B 0.00
AEterna Zentaris (AEZS) United States $0.020B 0.00
Soligenix (SNGX) United States $0.019B 0.00
CollPlant Holdings (CLGN) Israel $0.017B 0.00
Prana Biotechnology (ATHE) Australia $0.017B 0.00
Bionano Genomics (BNGO) United States $0.015B 0.00
TOCAGEN INC (TOCA) United States $0.014B 0.00
Pulmatrix (PULM) United States $0.014B 0.00
MYOS RENS Technology (MYOS) United States $0.013B 0.00
IBio (IBIO) United States $0.012B 0.00
IMMURON (IMRN) Australia $0.012B 0.00
Cleveland BioLabs (CBLI) United States $0.010B 0.00
TRACON Pharmaceuticals (TCON) United States $0.010B 0.00
Genetic Technologies (GENE) Australia $0.009B 0.00
Benitec Biopharma (BNTC) Australia $0.009B 0.00
TrovaGene (TROV) United States $0.007B 0.00
Cyclacel Pharmaceuticals (CYCC) United States $0.006B 0.00
Advaxis (ADXS) United States $0.006B 0.00
BioPharmX (BPMX) United States $0.005B 0.00
Titan Pharmaceuticals (TTNP) United States $0.003B 0.00
Neuralstem (CUR) United States $0.003B 0.00